Home > News
Larotrectinib for treating advanced solid tumours with TRK fusions [ID1299]

 Oncodna logo - wideToggle main menu visibility

DRUG TARGETS: NTRK - The UK regulator NICE has approved the use of larotrectinib for patients with advanced NTRK fusion position solid tumours, in both adults and children.
April 27, 2020
Larotrectinib for treating advanced solid tumours with TRK fusions [ID1299]
In development [GID-TA10229]<wbr></wbr> Expected publication date: 27 May 2020
To appraise the clinical and cost effectiveness of larotrectinib within its marketing authorisation for treating NTRK fusion-positive advanced solid tumours.
StatusIn progress
ProcessSTA 2018
ID number1299
Provisional Schedule
Final appraisal document21 April 2020 - 06 May 2020
Expected publication27 May 2020
Project Team
Project leadKate Moore
Email enquiries
If you have any queries please email tacommd@nice.org.uk
Evidence Review Group / Assessment GroupCentre for Reviews and Dissemination and Centre for Health Economics, University of York
Companies sponsorsBayer
OthersDepartment of Health and Social Care
 NHS England
 Welsh Government
Patient carer groupsGIST Support UK
 Roy Castle Lung Cancer Foundation
 Sarcoma UK
Professional groupsAssociation of Cancer Physicians
 Cancer Research UK
 Royal College of Pathologists
 Royal College of Physicians
 Society and College of Radiographers
Comparator companiesJanssen-Cilag Ltd
General commentatorsAll Wales Therapeutics and Toxicology Centre
 British National Formulary
 Department of Health, Social Services and Public Safety for
 Healthcare Improvement Scotland
 Scottish Medicines Consortium
 Welsh Health Specialised Services Committee
Relevant research groupsInstitute of Cancer Research
Key events during the development of the guidance:
03 April 2020Committee meeting: 2
04 March 2020Committee meeting: 2
17 January 2020 - 07 February 2020Appraisal consultation
20 November 2019Committee meeting
20 March 2019Invitation to participate
16 October 2018This appraisal has been rescheduled to allow the company to include important data to be presented in their submission. This delay means that this appraisal will be removed from the NICE’s reporting targets for timeliness. In addition, through this request for delay the company accepts that this drug will not be eligible to receive interim CDF funding from the date of marketing authorisation. The appraisal is now anticipated to begin during early April 2019.
20 September 2018 (10:00)Scoping workshop (London)
19 July 2018 - 16 August 2018Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
11 August 2017In progress, In progress